A Chinese medicine composition for treating cor pulmonale and its underlying diseases

Abstract

The invention discloses a Chinese medicine composition for treating pulmonary heart disease and its basic diseases, which is composed of the following raw materials in parts by weight: Panax notoginseng, turmeric, sophora flavescens, angelica, herba scutellariae, terrestris, clover, rhododendron, polygonum cuspidatum, ginseng, and houttuynia. The invention has a good curative effect on treating pulmonary heart disease and its basic diseases through the mutual cooperation and coordination between the raw materials.

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine composition for treating cor pulmonale and its underlying diseases. Background Art

[0002] Pulmonary heart disease, also known as cor pulmonale, is caused by various damaging factors that repeatedly damage the lungs, leading to damage to lung tissue, a decrease in effective and unobstructed capillaries, and contraction and remodeling of small blood vessels. This in turn increases pulmonary circulation resistance, increases pulmonary artery pressure, and increases right ventricular load. Due to excessive load, the heart becomes thickened or dilated, with or without right heart congestive heart failure. Once the condition enters the irreversible late stage, the efficacy of both Chinese and Western medicine is very poor. According to statistics, chronic obstructive pulmonary disease accounts for 81.8% of the causes of cor pulmonale in China. Other diseases such as bronchial asthma, severe pulmonary tuberculosis, bronchiectasis, pneumoconiosis, interstitial lung disease, etc., can also lead to chronic cor pulmonale in the late stage.

[0003] Western medicine uses low-flow oxygen inhalation, sulosemide diuretics, phentolamine and other vasodilators; deacetyl scutellariae and other cardiotonic drugs; select sensitive antibiotics for anti-infection treatment based on sputum culture sensitivity test; relieve cough, expectorant, asthma, clear the airway, improve respiratory function; diuretics, correct water electrolyte and acid-base imbalance, correct hypoxia and carbon dioxide retention, and use respiratory stimulants and glucocorticoids as appropriate. Conventional treatment measures, most patients with right heart failure can only alleviate heart failure after controlling infection and improving respiratory function, which improves the patient's health to a certain extent, but the clinical effect is not ideal, and it is easy to relapse. Long-term use of chemical drugs will have some potential risks, and will also produce some drug resistance. The main side effects are dysbiosis, superinfection, etc. Summary of the invention

[0004] The purpose of the present invention is to improve the deficiencies of the prior art and provide an oral Chinese medicine composition for treating cor pulmonale and its underlying diseases, which can effectively improve or even eliminate the clinical symptoms of patients and has the characteristics of significant therapeutic effect, short treatment cycle, no toxic side effects, etc. In particular, it has a significant effect in treating cor pulmonale caused by chronic bronchitis or chronic obstructive pulmonary disease.

[0005] In recent years, Chinese medicine has played an increasingly important role in the treatment of cor pulmonale. It has become an important treatment option for patients due to its relatively low cost, strong compliance and small side effects. The present invention is made of traditional Chinese herbal medicines. According to the holistic view of Chinese medicine, syndrome differentiation and treatment and several principles of modern medicine, the Chinese medicine composition is formed by orderly matching of natural extracts with certain components and clear effects to effectively treat chronic cor pulmonale.

[0006] The invention provides a traditional Chinese medicine for treating pulmonary heart disease and underlying diseases thereof. The traditional Chinese medicine is composed of the following raw materials in parts by weight: 5-10 parts by weight of Panax notoginseng, 5-10 parts by weight of Curcuma longa, 5-10 parts by weight of Sophora flavescens, 6-12 parts by weight of Herba Angelicae Sinensis, 9-18 parts by weight of Stephania tetrandrae, 9-18 parts by weight of Tripterygium wilfordii, 9-18 parts by weight of Rhododendron edulis, 10-20 parts by weight of Polygonum cuspidatum, 15-30 parts by weight of Panax notoginseng, and 15-30 parts by weight of Houttuynia cordata.

[0007] In a preferred embodiment, the traditional Chinese medicine composition for treating pulmonary heart disease and its underlying diseases is composed of the following raw materials in parts by weight: 10 parts by weight of Panax notoginseng, 10 parts by weight of Curcuma longa, 10 parts by weight of Sophora flavescens, 12 parts by weight of Herba Angelicae Sinensis, 18 parts by weight of Stephania tetrandra, 18 parts by weight of Tripterygium wilfordii, 18 parts by weight of Azalea leaves, 20 parts by weight of Polygonum cuspidatum, 30 parts by weight of Panax notoginseng, and 30 parts by weight of Houttuynia cordata.

[0008] Among them, Angelica sinensis: sweet, pungent, warm. It enters the heart, liver, and spleen meridians. It nourishes blood, promotes blood circulation, regulates menstruation and relieves pain, and moistens the intestines and promotes bowel movements.

[0009] Houttuynia cordata: pungent, cold. Enters the lung and liver meridians. Clears away heat and detoxifies, discharges pus and eliminates mediocrity, and promotes diuresis and relieves phlegm.

[0010] Blue flower ginseng: sweet, neutral. Enters the spleen and heart. Replenishes qi, replenishes deficiency, and relieves exterior symptoms.

[0011] Polygonum cuspidatum: slightly bitter, slightly cold. Enter the liver, gallbladder, and lung meridians. Dispel wind and dampness, disperse blood stasis and relieve pain, relieve cough and resolve phlegm.

[0012] Sophora flavescens: bitter, cold. Enters the heart, liver, stomach, large intestine, and bladder meridians. Clears away heat and dampness, kills insects, and is a diuretic.

[0013] Powdered Stephania tetrandra: bitter, cold. Enters bladder and lung meridians. Promotes diuresis and reduces swelling, dispels wind and relieves pain.

[0014] Three-leaf green: slightly bitter, neutral. Enters the spleen and stomach meridians. Clears away heat and detoxifies, dispels wind and resolves phlegm, promotes blood circulation and relieves pain.

[0015] Lucky Grass: sweet; cool. Clears the lungs and relieves cough; cools blood and stops bleeding; detoxifies and relieves sore throat.

[0016] Azalea leaves: sweet; neutral in nature. Enters the heart meridian. Nourishes and replenishes the body; detoxifies and kills insects; promotes blood circulation and relieves pain.

[0017] Bamboo Ginseng: sweet, slightly bitter, warm. Enter the liver, spleen, and lung meridians. Dissipate blood stasis and stop bleeding, reduce swelling and relieve pain, remove phlegm and relieve cough, and replenish the body and strengthen the body.

[0018] Turmeric: pungent, bitter, warm. Enters the spleen and liver meridians. Breaks up blood and promotes the flow of qi, dredges menstruation and relieves pain.

[0019] From January 2014 to December 2023, 100 patients of the present invention were taken, aged 36-72 years, and the course of disease was 8-31 years. All patients met the diagnostic criteria for chronic cor pulmonale formulated by the National Cor Pulmonale Conference, and all patients were accompanied by varying degrees of chest tightness, palpitation, shortness of breath, cough, expectoration, fatigue, cyanosis, dyspnea, chronic bronchitis, emphysema, lung infection, pulmonary hypertension, right ventricular enlargement or right heart failure, myocardial ischemia, right bundle branch block, atrial fibrillation and other symptoms. As the disease progresses, right heart failure and respiratory failure occur, such as palpitations and shortness of breath, cyanosis, headache, irritability, delirium, convulsions, and even coma. Among them, 60 were male and 40 were female; 48 patients had a history of long-term smoking, 10 had left ventricular failure, 46 had varying degrees of jugular vein distension, and 38 had varying degrees of lower limb edema; 52 patients had coarsened lung texture and small patchy shadows; 23 patients had coarsened lung texture and large dense shadows. Routine examination showed that 52 patients had a total white blood cell count <10×109 / L, accounting for 52%; 51 patients had serum albumin <30g / L, accounting for 51%; 48 patients had a neutrophil-to-white blood cell ratio >0.75, accounting for 48%. The most commonly used clinical classification of heart function is the New York Heart Association (NYHA) heart function classification. Class I: physical activity is not limited, and general physical activity does not cause excessive fatigue, palpitations, shortness of breath, and angina. Class II: mild physical activity limitation, general physical activity can cause symptoms such as palpitations and shortness of breath. Grade III: Physical activity is obviously limited, but normal even when resting. Even lower than the daily activity level can cause palpitations and shortness of breath. Grade IV: Physical activity is completely lost, but palpitations and shortness of breath still occur even when resting. Among them, 18 cases were in grade II, 22 in grade III, and 60 in grade IV. The clinical classification was mild in 18 cases, moderate in 22 cases, and severe in 60 cases.

[0020] Western medicine disease efficacy standard: markedly effective: after medication treatment, the dyspnea grading index of the patient decreased by 2 levels, or decreased to 1 level; lung rales disappeared or significantly reduced, cyanosis disappeared or significantly reduced, the patient's blood viscosity decreased significantly, jugular vein distension and lower limb edema basically disappeared, heart rate did not exceed 100 beats / min, PaO2 increased by more than 20mmHg, cardiopulmonary function was significantly restored, and cardiac function improved by 2 levels or reached level I compared with before; effective: after medication treatment, dyspnea was alleviated, lung rales were reduced, cyanosis was alleviated, heart rate did not exceed 110 beats / min, PaO2 increased by 10~20mmHg, cardiopulmonary function, respiratory function, blood viscosity, jugular vein distension and lower limb edema were all improved, and cardiac function was improved by 1 level compared with before; ineffective: before and after treatment, the patient's various functional indicators did not improve significantly, or the symptoms were consistent with those before treatment. Total effective = markedly effective + effective.

[0021] TCM disease efficacy criteria: markedly effective: wheezing, coughing, sputum, swelling and other symptoms disappeared, and laboratory tests were significantly improved; effective: wheezing, coughing, sputum, swelling and other symptoms were significantly improved, and laboratory tests were improved. Ineffective: main symptoms did not improve or worsened.

[0022] Patients take this prescription for treatment, one dose per day, decoct 100-150ml in water, divide into two portions, take one portion in the morning and one portion in the evening, 3 months as one course of treatment, and treat for 2 courses in a row. After taking the present invention for one course of treatment, 40 cases were markedly effective, 46 cases were effective, 13 cases were stable, 1 case was ineffective, and the effectiveness was 99%; after taking the present invention for two courses of treatment, 36 cases were nearly controlled, 42 cases were markedly effective, 18 cases were effective, 4 cases were stable, and the effectiveness was 100%; long-term use significantly improves the near control rate. Taking the drug of the present invention can improve the clinical symptoms of patients, significantly reduce erythropoietin (EPO), pulmonary artery (PASP), arterial carbon dioxide partial pressure (PaCO2), endothelin (ET), and whole blood viscosity, significantly increase brain natriuretic peptide (BNP), forced vital capacity (FVC), forced vital capacity in 1 second (FEV1), static vital capacity (SVC), arterial oxygen partial pressure (PaO2), and blood oxygen saturation (SaO2), significantly improve the respiratory function of patients, significantly reduce the pulmonary hypertension of patients, reduce the right heart load, quickly restore the heart function of patients, improve the quality of life of patients, and the therapeutic effect is significantly better than that of western medicine. The therapeutic effect of treating cor pulmonale is very significant, treating both the symptoms and the root cause, having a good effect after recovery, and not prone to recurrence.

[0023] Table 1: Comparison of improvement of main symptoms after treatment Symptoms disappeared, symptoms were alleviated, effective rate % Cough 100 78 21 1 99 Expectoration 100 76 23 1 99 Palpitations 75 60 13 2 97.33 Cyanosis 90 69 20 1 98.89 Edema 96 77 18 1 98.96 Wet rales 100 88 11 1 99 Breathing 100 83 15 2 98 Dyspnea 88 74 13 1 98.86 Table 2: Comparison of cardiac function before and after treatment Treatment time Heart function level I Heart function level II Heart function level III Heart function level IV Before treatment 0 18 22 60 After treatment 73 14 8 5 Table 3: Comparison of cardiopulmonary function related indicators before and after treatment Index Before treatment After treatment PASP (mm Hg) 670.56±8.52; 53.32±6.59 21±1.53; 7±1.43 BNP (pg / mL) 1842.2±446.7 231.23±35.13 FVC(L) 2.42+0.11 3.78±0.62 FEV1 (L) 1.24±0.25 2.83±0. 16 SVC 1.6±0.3; 1.1±0.1 3.8±0.3 2.6±0.2 PaO2 45.3±5.8 91.70±11.50 PaCO2 mm Hg 67.20±4.52 32.30±4.41 SaO2 (%) 63±4 96±3 Whole blood viscosity 8.3±1.1 4.08±0.42 ET (pg / ml) 2.4±0.3 1.1±0.2 During the treatment process, the patient did not experience any toxic side effects, and long-term use has no adverse effects, so it is relatively safe.

[0024] Animal experiments Experimental animals: 55 male SD rats (220-250g) aged about 6-8 weeks were selected and housed in SPF animal rooms at a density of 5 rats / cage, with a constant room temperature of 16 to 24°C, a 12-hour light / dark cycle, and a humidity of 50%. They were fed with standard feed and had free access to food and water. After 3 days of adaptive feeding, 12 rats were randomly selected as the normal group and the remaining 48 rats were selected as the modeling group. Their body weight was measured once a week. During the entire experiment, the rats were free to take ordinary feed and drink purified water.

[0025] Monocrotaline solvent preparation Dissolve 500 mg of monocrotaline in 4 ml of anhydrous ethanol. After it is completely dissolved, add 15 ml of normal saline, mix thoroughly, and use it immediately.

[0026] Preparation of rat model: 15 SD rats were randomly selected and injected with the above monocrotaline solution at a dose of 50 mg / kg once for modeling. After 3 weeks, heart and lung tissues were taken, fixed with 10% formalin, dehydrated with alcohol, transparent with xylene, embedded in paraffin, and sliced. Pathological observation under light microscope showed focal necrosis and inflammation of lung tissue, pulmonary congestion, interstitial hyperplasia, chronic inflammatory cell infiltration, increased lung wet weight and dry weight coefficient, and right ventricular hypertrophy, that is, cor pulmonale modeling was successful, and all 15 rats were successfully modeled.

[0027] Observation of general condition during modeling: During the experiment, the body shape, fur color changes, activity status, drinking water, eating and other general conditions of the two groups of experimental rats were observed and recorded. It was found that the rats in the normal group gradually gained weight, had shiny fur, were in good mental state, had normal diet, posture, and defecation, were sensitive to reaction, and moved freely. Rats in the model group began to sneeze after 2 days. About 7 days later, the symptoms of coughing and sneezing were obvious, the spirit was depressed, the fur was dry, the activity was gradually reduced, the weight was gradually reduced, the reaction was slow, the sensitivity to external reactions was reduced, and some rats had loose stools. After 21 days, the rats' airway secretions increased, sputum sounds could be heard, the diet and water intake decreased, the fur was loose, withered and dull, the mouth and tongue were purple, and obvious arched backs and curled up phenomena could be seen. The reaction to external stimuli was significantly reduced, the urine was yellow, and the stool was loose. The rats in the other groups were in poor spirits, reduced reactions, dull hair, dull eyes, and no obvious abnormalities in diet and defecation.

[0028] Treatment experiment: After successful modeling, the rats were divided into normal group, model group, Ruyi Dingchuan tablet group, low-dose group and high-dose group, with 10 rats in each group. Rats in the normal group and model group were gavaged with distilled water, and Ruyi Dingchuan tablets were gavaged once in the morning and evening with a solution containing 375 mg / mL of Ruyi Dingchuan tablets prepared with distilled water. The low-dose group was gavaged with 5 grams of Rhizoma Bamboo Joints, 5 grams of Rhizoma Curcumae, 5 grams of Rhizoma Sophorae Flavescentis, 6 grams of Radix Angelicae Sinensis, 6 grams of Herba Lucidae, 9 grams of Radix Stephaniae Tetrandrae, 9 grams of Rhizoma Azaleae, 9 grams of Tripterygium Wrightii, 10 grams of Polygonum Cuspidati, 15 grams of Radix Glehniae, and 15 grams of Herba Houttuyniae in the morning and evening every day; the high-dose group was gavaged with 10 grams of Rhizoma Bamboo Joints, 10 grams of Rhizoma Curcumae, 10 grams of Rhizoma Sophorae Flavescentis, 12 grams of Radix Angelicae Sinensis, 12 grams of Herba Lucidae, 18 grams of Radix Stephaniae Tetrandrae, 18 grams of Rhizoma Azaleae, 18 grams of Tripterygium Wrightii, 20 grams of Polygonum Cuspidati, 30 grams of Radix Glehniae, and 30 grams of Herba Houttuyniae in the morning and evening every day. The low-dose and high-dose of the present invention were decocted 2 times together according to the common decoction method, and continued to be decocted to 50ml, divided into 5 portions, one portion per day, divided into 2 morning and evening gavages. The low-dose group was equivalent to 18.8 grams / day of crude drugs, and the high-dose group was equivalent to 37.6 grams / day of crude drugs, and the two groups of medications were suitable for human body. The intragastric volume of each group was 1 ml / 100 g.

[0029] Statistical processing of data: SPSS data analysis software was used to obtain the mean value and error value s of each group. The results were expressed as ±s. Two independent samples were compared, and the difference in the mean values ​​of the two samples was obtained. The differences between *P or **P and the normal group, #P and ##P and the model group, and P@ or P@@ and the Ruyi Dingchuan tablets group were significant or extremely significant, and all were statistically significant.

[0030] Analysis of the mechanism of action of the present invention in treating cor pulmonale Observation of general conditions during the treatment experiment: record hair, breathing, flexibility, mental state and defecation, pay special attention to the cough, sneeze, wheeze and sputum of the model rats. The results of this experiment can confirm that the general conditions of the rats in the medication group of the present invention such as cough, sneeze, wheeze and sputum are improved after treatment.

[0031] After the adaptive feeding was completed, the experimental rats were weighed as the initial body weight. The rats were measured before being killed on the 56th day as the final body weight. The difference between the two values ​​was used to calculate the body weight gain, see Table 4.

[0032] Myocardial hypertrophy index: After the experiment, 8 rats in each group were killed, and the rat hearts were quickly removed and cleaned with normal saline. The ventricles were separated into right ventricle, left ventricle and ventricular septum along the lower part of the left and right atrial appendages, rinsed again, dried with filter paper, weighed and the right heart hypertrophy index was calculated.

[0033] Right heart hypertrophy index = right ventricular mass / (left ventricular mass + ventricular septum mass), see Table 4.

[0034] Table 4 Comparison of body weight gain and right heart hypertrophy index of rats in each group ± s Group Body weight gain Right ventricular hypertrophy index Normal group 256.6±11.73 0.234±0.015 Model group 164±11.32 0.472±0.126** Ruyi Dingchuan Tablets Group 221±13.41* 0.392±0.104# Low dose group 253±14.8@# 0.284±0.043##@ High dose group 268±12.51@# 0.241±0.051##@@ Note: Compared with the normal group, *P<0.05, **P<0.01 (the same below); compared with the model group, #P<0.05, ##P<0.01 (the same below); compared with the Yidingchuan tablets group, @P<0.05, @@P<0.01 (the same below).

[0035] Pathological changes of lung tissue in each group: The upper lung tissue was taken and fixed in formalin-acetic acid-ethanol fixative to make wax blocks. After slicing with a microtome, the tissue was routinely dewaxed, dehydrated, and transparent. Light microscopy showed that the lung tissue structure of rats in the normal group was clear, the alveoli were intact, and the structures of the alveoli, pulmonary interstitium, and pulmonary arterioles were normal. In the model group, the pulmonary artery wall was thickened, capillary congestion was obvious, the pulmonary artery and alveolar wall were obviously fibrotic and the lumen was narrowed, the alveolar septum was obviously thickened, some alveoli were cystic, and there was light red edema fluid in the alveoli. Macrophage infiltration in a large area of ​​pulmonary interstitium was extensive, and the lesions were extensive. Compared with the model group, the light red edema fluid in the alveoli of each group treated by the present invention was significantly reduced, the alveolar edema was significantly reduced, the fibrosis of the pulmonary artery and alveolar wall was significantly reduced, the thickness of the alveolar septum was significantly reduced, and the macrophage infiltration in the pulmonary interstitium was also significantly reduced. The treatment groups of the present invention were significantly better than the Ruyi Dingchuan tablet treatment group.

[0036] The EMMS FM animal forced lung function test system was used to test the tidal volume (VT), respiratory rate (RR), airway resistance (Raw), functional residual capacity (FRC), maximum ventilation volume (MVV), and respiratory muscle strength (Vmax) of rats in each group. See Table 5 Table 5: Lung function ± s in each group of rats Group VT ml: RR: times / min Raw: cmH2O / L / s FRC: ml MVV: L / min Vmax: cmH2O Normal group 4.8±0.3 60±5 0.8±0.2 2.0±0.2 120±10 10.5±1.2 Model group 3.4±0.4* 75±6* 1.5±0.3** 1.5±0.3* 80±10** 7.5±1.0** Ruyi Dingchuan Tablets Group 3.9±0.3# 68±5# 1.2±0.2# 1.8±0.1# 90±10# 8.5±1.2# Low dose 4.2±0.4#@ 63±6#@ 1.0±0.3#@ 1.9±0.3#@ 105±10#@ 9.6±1.5#@ High-dose group 4.7±0.3##@@ 61±5##@ 0.9±0.1##@ 2.0±0.1#@ 118±10##@ 10.5±1.1##@ The experimental results show that after intervention with two doses of the Chinese medicine composition, tidal volume, functional residual capacity, maximum ventilation, and respiratory muscle strength increased significantly; respiratory rate and airway resistance decreased significantly, indicating that the Chinese medicine composition of the present invention can significantly improve airflow limitation.

[0037] In summary, the present invention can effectively alleviate symptoms such as airflow limitation and continuous decline in lung function, and improve lung inflammation, so it can be clinically applied to diseases such as COPD, chronic bronchitis, and asthma.

[0038] The invention contains multiple chemical components, can target multiple targets of cor pulmonale and its underlying diseases, can significantly delay the progression of the disease, and can be used throughout the entire process of treating cor pulmonale and its underlying diseases. After treatment, the patient's quality of life is fundamentally improved.

[0039] Safety evaluation: No discomfort symptoms and signs related to medication occurred during the treatment process, indicating that the present invention has no obvious toxic and side effects, is highly safe, and is convenient for patients to take it for a long time. Patients have not had any adverse reactions after taking the medicine for nearly many years.

[0040] The present invention also provides an oral preparation made from the above-mentioned Chinese medicine composition for treating cor pulmonale and its underlying diseases, the oral preparation comprising oral liquid, tablets, capsules, pills, etc. The preferred dosage form is tablets and capsules, one dose per day, taken twice a day, morning and evening.

[0041] The Chinese medicine composition of the present invention can be prepared into various dosage forms. For example, the decoction liquid is sterilized and then bagged to make an oral liquid; or the decoction liquid is concentrated, dried, and then medically acceptable auxiliary materials are added to make tablets, capsules, pills, etc.

[0042] The medically acceptable excipients include starch, dextrin, sodium carboxymethyl cellulose, polyethylene glycol, calcium hydrogen phosphate, sodium alginate, potassium sorbate and the like.

[0043] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any form. Those skilled in the art may make some simple modifications, equivalent changes or modifications using the technical contents disclosed above, which all fall within the protection scope of the present invention.

Claims

1. A Chinese medicine for treating cor pulmonale and its underlying diseases, characterized by The invention is composed of the following raw materials in parts by weight: 5-10 parts by weight of Panax notoginseng, 5-10 parts by weight of Curcuma longa, 5-10 parts by weight of Sophora flavescens, 6-12 parts by weight of Herba Angelicae Sinensis, 9-18 parts by weight of Stephania tetrandrae, 9-18 parts by weight of Tripterygium wilfordii, 9-18 parts by weight of Rhododendron edulis, 10-20 parts by weight of Polygonum cuspidatum, 15-30 parts by weight of Panax notoginseng, and 15-30 parts by weight of Houttuynia cordata.

2. A Chinese medicine for treating cor pulmonale and its underlying diseases according to claim 1, characterized in that The drug composition comprises the following raw materials in parts by weight: 10 parts by weight of Panax notoginseng, 10 parts by weight of Curcuma longa, 10 parts by weight of Sophora flavescens, 12 parts by weight of Herba Angelicae Sinensis, 18 parts by weight of Stephania tetrandra, 18 parts by weight of Tripterygium wilfordii, 18 parts by weight of Rhododendron edulis, 20 parts by weight of Polygonum cuspidatum, 30 parts by weight of Panax notoginseng, and 30 parts by weight of Houttuynia cordata.

3. An oral preparation for treating cor pulmonale and its underlying diseases, characterized by Made from the Chinese medicine composition according to any one of claims 1 or 2.

4. The oral preparation for treating cor pulmonale and its underlying diseases according to claim 3, characterized in that The preparations include oral liquid, tablets, capsules and pills, with oral liquid and tablets being preferred.